Neurobehavioral risks of SSRIs in pregnancy: Comparing human and animal data

Reproductive Toxicology

Volumn 72, Issue , 2017, Pages 191-200

  Ornoy, Asher ^a  

^a HEBREW UNIVERSITY   (Israel)

Author keywords

Animal studies; ASD; Neurodevelopmental effects; SNRIs; SSRIs

Indexed keywords

SEROTONIN UPTAKE INHIBITOR;

AUTISM; CHILD DEVELOPMENT; COGNITIVE DEFECT; DEPRESSION; DISEASE ASSOCIATION; EPIGENETICS; HIGH RISK BEHAVIOR; HIGH RISK PREGNANCY; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LANGUAGE ABILITY; NONHUMAN; PREGNANCY OUTCOME; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; TERATOGENICITY; UPREGULATION; ANIMAL; BEHAVIOR; DRUG EFFECT; FEMALE; FETOMATERNAL TRANSFUSION; GENETIC EPIGENESIS; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; PREGNANCY;

ANIMALS; AUTISM SPECTRUM DISORDER; BEHAVIOR; EPIGENESIS, GENETIC; FEMALE; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MATERNAL-FETAL EXCHANGE; PITUITARY-ADRENAL SYSTEM; PREGNANCY; SEROTONIN UPTAKE INHIBITORS;

EID: 85019458641     PISSN: 08906238     EISSN: 18731708     Source Type: Journal    
DOI: 10.1016/j.reprotox.2017.05.003     Document Type: Review

References (90)

1. Berger, M., Gray, J.A., Roth, B.L., The expanded biology of serotonin. Annu. Rev. Med. 60 (2009), 355–366.
2. Young, S.N., How to increase serotonin in the human brain without drugs. Rev. Psychiatry Neurosci. 32 (2007), 394–399.
3. Oberlander, T.F., Fetal serotonin signalling: setting pathways for early childhood development and behavior. J. Adolesc. Health 51:2 Suppl (2012), S9–S16.
4. Monti, J.M., Serotonin control of sleep–wake behavior. Sleep Med. Rev. 15:4 (2011), 269–281.
5. Gavin, N.I., Gaynes, B.N., Lohr, K.N., Melzer-Brody, S., Gartlehner, G., Swinson, T., Perinatal depression; a systematic review of prevalence and incidence. Obstet. Gynecol. 106 (2005), 1071–1083.
6. Bennett, H.A., Einarson, A., Taddio, A., Koren, G., Einarson, T.R., Prevalence of depression during pregnancy: systematic review. Obstet. Gynecol. 103 (2004), 698–709.
7. Cooper, W.O., Willy, M.E., Pont, S.J., Ray, W.A., Increasing use of antidepressants in pregnancy. Am. J. Obstet. Gynecol. 196 (2007), 544e1–544e5.
8. Diav-Citrin, O., Ornoy, A., Selective serotonin reuptake inhibitors in human pregnancy: to treat or not to treat. Obstet. Gynecol. Int., 2012, 1–12 (open access article).
9. Huybrechts, K.F., Bateman, B.T., Palmsten, K., Desai, R.J., Patorno, E., Gopalakrishnan, C., et al. Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn. JAMA 313:21 (2015), 2142–2151.
10. Ornoy, A., Koren, G., Selective serotonin reuptake inhibitors in human pregnancy: on the way to resolving the controversy. Semin. Fetal Neonatal Med. 19:3 (2014), 188–194.
11. Hendrick, V., Stowe, Z.N., Altshuler, L.L., Hwang, S., Lee, E., Haynes, D., Placental passage of antidepressant medications. Am. J. Psychiatry 160 (2003), 993–996.
12. Rampono, J., Simmer, K., Ilett, K.F., Hackett, L.P., Doherty, D.A., Elliot, R., et al. Placental transfer of SSRI and SNRI antidepressants and effects on the neonate. Pharmaco-psychiatry 42 (2009), 95–100.
13. Eke, A.C., Saccone, G., Berghella, V., Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and risk of preterm birth: a systematic review and meta-analysis. BJOG 123:12 (2016), 1900–1907.
14. Malm, H., Sourander, A., Gissler, M., Gyllenberg, D., Hinkka-Yli-Salomäki, S., McKeague, I.W., et al. Pregnancy complications following prenatal exposure to SSRIs or maternal psychiatric disorders: results from population-based national register data. Am. J. Psychiatry 172:12 (2015), 1224–1232.
15. Diav-Citrin, O., Shechtman, S., Weinbaum, D., Wajnberg, R., Avgil, M., Arnon, J., et al. Paroxetine and fluoxetine in pregnancy: a prospective, multi-center, controlled, observational study. Br. J. Clin. Pharmacol. 66:5 (2008), 695–705.
16. Huybrechts, K.F., Hernández-Díaz, S., Patorno, E., Desai, R.J., Mogun, H., Dejene, S.Z., et al. Antipsychotic use in pregnancy and the risk for congenital malformations. JAMA Psychiatry 73:9 (2016), 938–946.
17. Levinson-Castiel, R., Merlob, P., Linder, N., Sirota, L., Klinger, G., Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch. Pediatr. Adolesc. Med. 160:2 (2006), 173–176.
18. Klinger, G., Frankenthal, D., Merlob, P., Diamond, G., Sirota, L., Levinson-Castiel, R., et al. Long-term outcome following selective serotonin reuptake inhibitor induced neonatal abstinence syndrome. J. Perinatol. 9 (2011), 615–620.
19. Ornoy, A., The impact of intrauterine exposure versus postnatal environment in neurodevelopment toxicity: long term neurobehavioral studies in children at risk for developmental disorders. Toxicol. Lett. 140/141 (2003), 171–181.
20. Ornoy, A., Segal, J., Bar-Hamburger, R., Greenbaum, C., The developmental outcome of school age children born to heroin-dependent mothers: importance of environmental factors. Dev. Med. Child. Neurol. 43 (2001), 668–675.
21. Hanley, G.E., Brain, U., Oberlander, T.F., Prenatal exposure to serotonin reuptake inhibitor antidepressants and childhood behavior. Pediatr. Res. 78:2 (2015), 174–180.
22. Mulder, E.J.H., Ververs, F.F.T., de Heus, R., Visser, G.H.A., Selective serotonin reuptake inhibitors affect neurobehavioral development in the human fetus. Neuropsychopharmacology 36:10 (2011), 1961–1971.
23. Ergaz, Z., Ornoy, A., Perinatal and early postnatal factors underlying developmental delay and disabilities. Dev. Disabil. Res. Rev. 17:2 (2011), 59–70.
24. Nulman, I., Rovet, J., Stewart, D.E., Wolpin, J., Gardner, H.A., Theis, J.G.W., et al. Neurodevelopment of children exposed in utero to antidepressants drugs. N. Engl. J. Med. 336 (1997), 258–262.
25. Nulman, I., Rovet, J., Stewart, D.E., Wolpin, J., Pace-Asciak, P., Shuhaiber, S., Koren, G., Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective controlled study. Am. J. Psychiatry 159 (2002), 1889–1895.
26. Nulman, I., Koren, G., Rovet, J., Barrera, M., Pulver, A., Streiner, D., Feldman, B., Neurodevelopment of children following prenatal exposure to venlafaxine, selected serotonin reuptake inhibitors, or untreated maternal depression. Am. J. Psychiatry 169 (2012), 1165–1174.
27. Nulman, I., Koren, G., Rovet, J., Barrera, M., Streiner, D.L., Feldman, B.M., Neurodevelopment of children prenatally exposed to selective serotonin reuptake inhibitor antidepressants: Toronto sibling study. J. Clin. Psychiatry 76:7 (2015), e842–e847.
28. Misri, S., Reebye, P., Kendrick, K., Carter, D., Ryan, D., Grunau, R.E., Oberlander, T.F., Internalizing behaviors in 4-year old children exposed in-utero to psychotropic medications. Am. J. Psychiatry 163 (2006), 1026–1032.
29. Oberlander, T.F., Reebye, P., Misri, S., Rapsdorf, M., Kim, J., Grunau, R.E., Externalizing and attentional behaviors in children of depressed mothers treated with a selective serotonin reuptake inhibitor antidepressant during pregnancy. Arch. Pediatr. Adolesc. Med. 161 (2007), 22–29.
30. Heikkinen, T., Ekblad, U., Kero, P., Ekblad, S., Laine, K., Citalopram in pregnancy and lactation. Clin. Pharmacol. Ther. 72:2 (2002), 184–191.
31. Casper, R.C., Fleisher, B.E., Lee-Ancajas, J.C., Gilles, A., Gaylor, E., DeBattista, A., Hoyme, H.E., Follow up of children of depressed mothers exposed or not exposed to antidepressants drugs during pregnancy. J. Pediatr. 142 (2003), 402–408.
32. Pedersen, L.H., Henriksen, T.B., Olsen, J., Fetal exposure to antidepressants and normal milestone development at 6 and 19 months of age. Pediatrics 125 (2010), e600–e608.
33. Hanley, G.E., Brain, U., Oberlander, T.F., Infant developmental outcomes following prenatal exposure to antidepressants, and maternal depressed mood and positive affect. Early Hum. Dev. 89:8 (2013), 519–524.
34. Santucci, A.K., Singer, L.T., Wisniewski, S.R., Luther, J.F., Eng, H.F., Dills, J.L., et al. Impact of prenatal exposure to serotonin reuptake inhibitors or maternal major depressive disorder on infant developmental outcomes. J. Clin. Psychiatry 75:10 (2014), 1088–1095.
35. Johnson, K.C., Smith, A.K., Stowe, Z.N., Newport, D.J., Brennan, P.A., Preschool outcomes following prenatal serotonin reuptake inhibitor exposure: differences in language and behavior, but not cognitive function. J. Clin. Psychiatry 77:2 (2016), e176–e182.
36. Weikum, W.M., Oberlander, T.F., Hensch, T.K., Werker, J.F., Prenatal exposure to antidepressants and depressed maternal mood alter trajectory of infant speech perception. Proc. Natl. Acad. Sci. U. S. A. 109:Suppl. 2 (2012), 17221–17227.
37. Brown, A.S., Gyllenberg, D., Malm, H., McKeague, I.W., Hinkka-Yli-Salomäki, S., Artama, M., et al. Association of selective serotonin reuptake inhibitor exposure during pregnancy with speech, scholastic, and motor disorders in offspring. JAMA Psychiatry 73:11 (2016), 1163–1170.
38. Malm, H., Brown, A.S., Gissler, M., Gyllenberg, D., Hinkka-Yli-Salomäki, S., McKeague, I.W., et al. Gestational exposure to selective serotonin reuptake inhibitors and offspring psychiatric disorders: a National Register-Based Study. J. Am. Acad. Child. Adolesc. Psychiatry 55:5 (2016), 359–366.
39. Harrington, R.A., Lee, L.C., Crum, R.M., Zimmerman, A.W., Hertz-Piccioto, I., Serotonin hypothesis of autism: implications for selective serotonin reuptake inhibitor use during pregnancy. Autism Res. 6 (2013), 149–163.
40. Croen, L.A., Grether, J.K., Yoshida, C.K., Odouli, R., Hendrick, V., Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch. Gen. Psychiatry 68 (2011), 1104–1112.
41. Harrington, R.A., Lee, L.C., Crum, R.M., Zimmerman, A.W., Hertz-Picciotto, I., Prenatal SSRI use and offspring with autism spectrum disorder or developmental delay. Pediatrics 133:5 (2014), e1241–e1248.
42. Clements, C.C., Castro, V.M., Blumenthal, S.R., Rosenfield, H.R., Murphy, S.N., Fava, M., et al. Prenatal antidepressant exposure is associated with risk for attention-deficit hyperactivity disorder but not autism spectrum disorder in a large health system. Mol. Psychiatry 20:6 (2015), 727–734.
43. Castro, V.M., Kong, S.W., Clements, C.C., Brady, R., Kaima, A.J., Doyle, A.E., et al. Absence of evidence for increase in risk for autism or attention-deficit hyperactivity disorder following antidepressant exposure during pregnancy: a replication study. Transl. Psychiatry 6 (2016), e708–e713.
44. Rai, D., Lee, B.K., Dalman, C., Golding, J., Lewis, G., Magnusson, C., Parental depression, maternal antidepressant use during pregnancy and risk of autism spectrum disorder; population based case–control study. BMJ, 346, 2013, f2059.
45. Sullivan, S., Rai, D., Golding, J., Zammit, S., Steer, C., The association between autism spectrum disorder and psychotic experience in the Avon longitudinal study of parents and children (ALSPAC) birth cohort. J. Am. Acad. Child Adolesce. Psychiatry 52 (2013), 806–814.
46. Hviid, A., Melbye, M., Pasternak, B., Use of selective serotonin reuptake inhibitors during pregnancy and risk of autism. N. Engl. J. Med. 369:25 (2013), 2406–2415.
47. Sørensen, M.J., Grønborg, T.K., Christensen, J., Parner, E.T., Vestergaard, M., Schendel, D., Pedersen, L.H., Antidepressant exposure in pregnancy and risk of autism spectrum disorders. Clin. Epidemiol. 15:5 (2013), 449–459.
48. Boukhris, T., Sheehy, O., Mottron, L., Bérard, A., Antidepressant use during pregnancy and the risk of autism spectrum disorder in children. JAMA Pediatr. 170:2 (2016), 117–124.
49. Man, K.K., Tong, H.H., Wong, L.Y., Chan, E.W., Simonoff, E., Wong, I.C., Exposure to selective serotonin reuptake inhibitors during pregnancy and risk of autism spectrum disorder in children: a systematic review and meta-analysis of observational studies. Neurosci. Biobehav. Rev. 49 (2015), 82–89.
50. Gentile, S., Prenatal antidepressant exposure and the risk of autism spectrum disorders in children. Are we looking at the fall of Gods?. J. Affect Disord. 182 (2015), 132–137.
51. Kaplan, Y.C., Keskin-Arslan, E., Acar, S., Sozmen, K., Prenatal selective serotonin reuptake inhibitor use and the risk of autism spectrum disorder in children: a systematic review and meta-analysis. Reprod. Toxicol. 66 (2016), 31–43.
52. Brown, H.K., Hussain-Shamsy, N., Lunsky, Y., Dennis, C.E., Vigod, S.N., The association between antenatal exposure to selective serotonin reuptake inhibitors and autism: a systematic review and meta-analysis. J. Clin. Psychiatry 78:1 (2017), e48–e58.
53. Byrd, R.A., Markham, J.K., Developmental toxicology studies of fluoxetine hydrochloride administered orally to rats and rabbits. Fundam. Appl. Toxicol. 22 (1994), 511–518.
54. Davies, T.S., Kluwe, W.M., Preclinical toxicological evaluation of sertraline hydrochloride. Drug Chem. Toxicol. 21 (1998), 521–537.
55. Shuey, D.L., Sadler, T.W., Lauder, J.M., Serotonin as a regulator of craniofacial morphogenesis: site specific malformations following exposure to serotonin uptake inhibitors. Teratology 46 (1992), 267–278.
56. Sari, Y., Zhou, F.C., Serotonin and its transporter on proliferation of fetal heart cells. Int. J. Dev. Neurosci. 21 (2003), 417–424.
57. Bengel, D., Murphy, D.L., Anderson, A.M., Wichens, C.H., Feltiner, D., Armin, H.E., et al. Altered brain serotonin homeostasis and locomotor insensitivity to 3,4-methylenedioxymethamphetamine (“Ecstasy”) in serotonin transporter-deficient mice. Mol. Pharmacol. 53 (1998), 649–655.
58. Oberlander, T.F., Gingrich, J.A., Ansorge, M.S., Sustained neurobehavioral effects of exposure to SSRI antidepressants during development: molecular to clinical evidence. Clin. Pharmacol. Ther. 86:6 (2009), 672–677.
59. Cao-Lei, L., Massart, R., Suderman, M.J., Machnes, Z., Elgbeili, G., Laplante, D.P., et al. DNA methylation signatures triggered by prenatal maternal stress exposure to a natural disaster: Project Ice Storm. PLoS One, 9(9), 2014, e107653.
60. Chauloff, F., Berton, O., Mormede, P., Serotonin and stress. Neuropsychopharmacology 21 (1999), 28S–32S.
61. Coleman, F.H., Christensen, H.D., Gonzalez, C.L., Rayburn, W.F., Behavioral changes in developing mice after prenatal exposure to paroxetine (Paxil). Am. J. Obstet. Gynecol. 181 (1999), 1166–1171.
62. 3 receptor-dependent cortical abnormalities and anxiety-like behavior. Neuropharmacology 62 (2012), 865–870.
63. Christensen, H.D., Rayburn, W.F., Gonzalez, C.L., Chronic prenatal exposure to paroxetine (Paxil) and cognitive development of mice offspring. Neurotoxicol. Teratol. 22:5 (2000), 733–739.
64. Bairy, K.L., Madhyastha, S., Ashok, K.P., Bairy, I., Malini, S., Developmental and behavioral consequences of prenatal fluoxetine. Pharmacology 79 (2007), 1–11.
65. Olivier, J.D., Vallès, A., van Heesch, F., Afrasiab-Middelman, A., Roelofs, J.J., Jonkers, M., et al. Fluoxetine administration to pregnant rats increases anxiety-related behavior in the offspring. Psychopharmacology (Berl). 217:3 (2011), 419–432.
66. Francis-Oliveira, J., Ponte, B., Barbosa, A.P., Veríssimo, L.F., Gomes, M.V., Pelosi, G.G., Britto, L.R., Moreira, E.G., Fluoxetine exposure during pregnancy and lactation: effects on acute stress response and behavior in the novelty-suppressed feeding are age and gender-dependent in rats. Behav. Brain Res. 252 (2013), 195–203.
67. Svirsky, N., Levy, S., Avitsur, R., Prenatal exposure to selective serotonin reuptake inhibitors (SSRI) increases aggression and modulates maternal behavior in offspring mice. Dev. Psychobiol. 58:1 (2016), 71–82.
68. Ehrlich, D.E., Neigh, G.N., Bourke, C.H., Nemeth, C.L., Hazra, R., Ryan, S.J., et al. Prenatal stress, regardless of concurrent escitalopram treatment, alters behavior and amygdala gene expression of adolescent female rats. Neuropharmacology 97 (2015), 251–258.
69. Glover, M.E., Pugh, P.C., Jackson, N.L., Cohen, J.L., Fant, A.D., Akil, H., Clinton, S.M., Early-life exposure to the SSRI paroxetine exacerbates depression-like behavior in anxiety/depression-prone rats. Neuroscience 284 (2015), 775–797.
70. Ansorge, M.S., Zhou, M., Lira, A., Hen, R., Gingrich, J.A., Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice. Science 306:5697 (2004), 879–881.
71. Maciag, D., Simpson, K.L., Coopinger, D., Lu, Y., Wang, Y., Lin, R.C., et al. Neonatal antidepressant exposure has lasting effects on behaviour and serotonin circuitory. Neuropsychopharmacology 31 (2006), 47–57.
72. Rayen, I., Steinbusch, H.W., Charlier, T.D., Pawluski, J.L., Developmental fluoxetine exposure and prenatal stress alter sexual differentiation of the brain and reproductive behavior in male rat offspring. Psychoneuroendocrinology 38:9 (2013), 1618–1629.
73. Boulle, F., Pawluski, J.L., Homberg, J.R., Machiels, B., Kroeze, Y., Kumar, N., et al. Developmental fluoxetine exposure increases behavioral despair and alters epigenetic regulation of the hippocampal BDNF gene in adult female offspring. Horm. Behav. 80 (2016), 47–57.
74. Gurnot, C., Martin-Subero, I., Mah, S.M., Weikum, W., Goodman, S.J., Brain, U., et al. Prenatal antidepressant exposure associated with CYP2E1 DNA methylation change in neonates. Epigenetics 10:50 (2015), 361–372.
75. Fuller, R.W., Mechanisms and functions of serotonin neuronal systems: opportunities for neuropeptide interactions. Ann. N.Y. Acad. Sci. 780 (1996), 176–184.
76. Fuller, R.W., Serotonin receptors involved in regulation of pituitary-adrenocortical function in rats. Behav. Brain Res. 73:1–2 (1996), 215–219.
77. Pariante, C.M., Risk factors for development of depression and psychosis. Glucocorticoid receptors and pituitary implications for treatment with antidepressant and glucocorticoids. Ann. N.Y. Acad. Sci. 1179 (2009), 144–152.
78. Ornoy, A., Reece, A.E., Pavlinkova, G., Kappen, C., Miller, R.K., Effect of maternal diabetes on the embryo, fetus and children: congenital anomalies, genetic and epigenetic changes and developmental outcomes. Birth Defects Res. Part C 105:1 (2015), 53–72.
79. Petropoulos, S., Guillemin, C., Ergaz, Z., Dimov, S., Suderman, M., Weinstein-Fudim, L., et al. Gestational Diabetes alters offspring DNA methylation profiles in human and rat: identification of key genes involved in endocrine system disorders, insulin signaling, diabetes signaling and IL-K signaling pathways. Endocrinology 156:6 (2015), 2222–2238.
80. Reynolds, R.M., Glucocorticoid excess and the developmental origins of disease: two decades of testing the hypothesis – 2012 Curt Richter Award Winner. Psychoneuroendocrinology 38:1 (2013), 1–11.
81. Brunton, P.J., Effects of maternal exposure to social stress during pregnancy: consequences for mother and offspring. Reproduction 146 (2013), 175–189.
82. Juruena, M.F., Cleare, A.J., Pariante, C.M., The hypothalamic pituitary adrenal axis, glucocorticoid receptor function and relevance to depression. Rev. Bras. Pisquitr. 26:3 (2004), 189–201.
83. Nikisch, G., Involvement and role of antidepressant drugs of the hypothalamic-pituitary-adrenal axis and glucocorticoid receptor function. Neuro Endocrinol. Lett. 30:1 (2009), 11–16.
84. Flandreau, E.I., Bourke, C.H., Ressler, K.J., Vale, W.W., Nemeroff, C.B., Owens, M.J., Escitalopram alters gene expression and HPA axis reactivity in rats following chronic overexpression of corticotropin-releasing factor from the central amygdala. Psychoneuroendocrinology 38:8 (2013), 1349–1361.
85. Avitsur, R., Grinshpahet, R., Goren, N., Weinstein, I., Kirshenboim, O., Chlebowski, N., Prenatal SSRI alters the hormonal and behavioral responses to stress in female mice: possible role for glucocorticoid resistance. Horm. Behav. 84 (2016), 41–49.
86. Bourke, C.H., Stowe, Z.N., Neigh, G.N., Olson, D.E., Owens, M.J., Prenatal exposure to escitalopram and/or stress in rats produces limited effects on endocrine, behavioral, or gene expression measures in adult male rats. Neurotoxicol. Teratol. 39 (2013), 100–109.
87. Salari, A.A., Fatehi-Gharehlar, L., Motayagheni, N., Homberg, J.R., Fluoxetine normalizes the effects of prenatal maternal stress on depression- and anxiety-like behaviors in mouse dams and male offspring. Behav. Brain Res. 311 (2016), 354–356.
88. Pawluski, J.L., Rayen, I., Niessen, N.A., Kristensen, S., van Donkelaar, E.L., Balthazart, J., et al. Developmental fluoxetine exposure differentially alters central and peripheral measures of the HPA system in adolescent male and female offspring. Neuroscience 220 (2012), 131–141.
89. Oberlander, T.F., Grunau, R., Mayes, L., Riggs, W., Rurak, D., Papsdorf, M., et al. Hypothalamic-pituitary-adrenal (HPA) axis function in 3-month old infants with prenatal selective serotonin reuptake inhibitor (SSRI) antidepressant exposure. Early Hum. Dev. 84:10 (2008), 689–697.
90. Pawluski, J.L., Brain, U.M., Underhill, C.M., Hammond, G.L., Oberlander, T.F., Prenatal SSRI exposure alters neonatal corticosteroid binding globulin, infant cortisol levels, and emerging HPA function. Psychoneuroendocrinology 37:7 (2012), 1019–1028.